Pilot Study of CBT With tDCS for Adults Being Treated for Obsessive Compulsive Disorder

Sponsor
Rogers Behavioral Health (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05964998
Collaborator
(none)
20
1
2
12
1.7

Study Details

Study Description

Brief Summary

This pilot study aims to compare the effect of transcranial direct current stimulation (tDCS) versus sham stimulation, delivered immediately prior to cognitive-behavioral therapy (CBT) for obsessive-compulsive disorder (OCD), on patient-reported outcomes. The investigator hypothesize that patients who receive active stimulation will experience greater improvement in OCD symptoms than those who receive sham stimulation.

Condition or Disease Intervention/Treatment Phase
  • Device: transcranial direct current stimulation
  • Device: Sham transcranial direct current stimulation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants randomized to either active tDCS stimulation or sham.Participants randomized to either active tDCS stimulation or sham.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Investigating Non-invasive Brain Stimulation to Enhance CBT in Intensive Treatment-seeking Patients With OCD
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active stimulation

Device: transcranial direct current stimulation
Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes

Sham Comparator: Sham stimulation

Device: Sham transcranial direct current stimulation
Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes

Outcome Measures

Primary Outcome Measures

  1. Change in Yale-Brown Obsessive-Compulsive Scale - Self-Report from admission to discharge [Up to 12 weeks]

  2. Change in Quick Inventory of Depressive Symptomology from admission to discharge [Up to 12 weeks]

Secondary Outcome Measures

  1. Number of treatment days between admission and discharge [Up to 12 weeks]

  2. Change in Obsessive-Compulsive Inventory-Revised from admission to discharge [Up to 12 weeks]

  3. Change in Quality of life enjoyment and satisfaction questionnaire - short form from admission to discharge [Up to 12 weeks]

  4. Change in Intolerance of uncertainty scale from admission to discharge [Up to 12 weeks]

  5. Change in Subjective units of distress from admission to discharge [Up to 12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Primary diagnosis of Obsessive-Compulsive Disorder (OCD)

  • Resident of state of Wisconsin

  • Enrolled in OCD Intensive Outpatient Program (IOP) at Rogers Behavioral Health in Oconomowoc, WI

  • Ability to communicate effectively using written and spoken English

Exclusion Criteria:
  • Metal in the body of any kind (e.g., braces, pacemakers, metal plates or screws, intracranial electrodes, implanted devices/defibrillators, prostheses)

  • Currently taking medication that reduces seizure threshold (e.g., clomipramine)

  • Cranial pathologies (e.g., holes, plates)

  • History of seizure or black-out concussion

  • Pregnancy

  • Previous treatment at Rogers Behavioral Health

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rogers Behavioral Health Oconomowoc Wisconsin United States 53066

Sponsors and Collaborators

  • Rogers Behavioral Health

Investigators

  • Principal Investigator: Bradley C Riemann, PhD, Rogers Behavioral Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rogers Behavioral Health
ClinicalTrials.gov Identifier:
NCT05964998
Other Study ID Numbers:
  • 22-ROGE-103
First Posted:
Jul 28, 2023
Last Update Posted:
Jul 28, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Rogers Behavioral Health
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 28, 2023